SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Apr 22, 2011

SEC Form 4/A — Form 4/A

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-04-13

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-04-13	Common Stock	A	120838	—	Acquired	126838	Direct

Footnotes

F1: The number of shares initally report to have been received pursuant to the Merger was incorrect.

F2: Received in exchange for 993,739 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.